Clinical trial
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4…
NCT00467519 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00467519 |
|---|---|
| Title | Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age |
| Official title | Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine as Fifth Dose Booster in Children 4 to 6 Years of Age |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tetanus, Diphtheria, Pertussis |
| Intervention type | Biological |
| Interventions | Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis), DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) |
| Enrollment | 1,045 |
| Start date | Apr 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Apr 30, 2007 |
| Last update posted | Feb 7, 2014 |
| Countries | Canada, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: